Additionally, AAV-induced RIPK3 expression can promote necroptosis in the TME, enhance neoantigen presentation activity, and induce tumor-specific CD8+ T-cell priming, resulting in secondary tumor control and improved therapeutic efficacy of immune checkpoint blockers in various tumor mouse models (58). The gene discussed is CD8A; the disease is neoplasm.